Cibc World Markets Corp Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Cibc World Markets Corp purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,674 shares of the biopharmaceutical company's stock, valued at approximately $558,000.

A number of other large investors also recently modified their holdings of the business. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $29,000. Smartleaf Asset Management LLC lifted its holdings in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics during the fourth quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust grew its holdings in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research analyst reports. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Benchmark reaffirmed a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Remove Ads

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company's stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 in the last 90 days. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Up 0.8 %

NASDAQ HALO traded up $0.49 on Tuesday, hitting $64.51. 162,281 shares of the stock were exchanged, compared to its average volume of 1,333,866. The company's 50-day moving average price is $58.39 and its two-hundred day moving average price is $54.68. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00. The company has a market capitalization of $7.97 billion, a price-to-earnings ratio of 18.79, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.